Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
2 Commerce Drive Cranbury, NJ 08512